Akili

Biotechnology – Healthcare

Prescription-only digital therapeutic in the form of a mobile video game. Akili’s lead program, EndeavorRx™, is the first ever US Food and Drug Administration (FDA) approved digital therapeutic (class II de novo software as a medical device) for the treatment of attention-deficit/hyperactivity disorder (ADHD). Akili is regarded as the industry leader in this field, their technology platform allows the modulation as well as quantification of cognition and has the potential to be applied across multiple neurodegenerative indications.

Akili was formed in 2011 by PureTech Health (NASDAQ: PRTC), a science-driven, cross-disciplinary healthcare technology R&D company located in Boston, MA. The company is based on the scientific research originating from the lab of Adam Gazzaley at University of California, San Francisco and supported by top-tier entertainment software creators (ex-Electronic Arts).